Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Secondary malignant neoplasm of lymph node
0.090 Biomarker disease BEFREE Reduced CDX2 was associated with lymph node metastasis (p = 0.0167), distant metastasis (p = 0.0123), and unfavorable survival (multivariate analysis: p = 0.0008; HR (95%CI) 0.922 (0.988-0.997)) as well as BRAF<sup>V600E</sup>, mismatch repair deficiency, and CpG island methylator phenotype. 30257705 2018
Secondary malignant neoplasm of lymph node
0.090 Biomarker disease BEFREE Patients with CDX2-negative metastatic CRC were significantly more likely to be female, and to have right-sided primary tumors, poorly differentiated histologic features, and distant lymph node metastasis. 27726953 2017
Secondary malignant neoplasm of lymph node
0.090 PosttranslationalModification disease BEFREE The methylation of the CDX2 promoter was associated with enhanced lymph node metastases and shorter survival time (p = 0.0273), but was independent of tumor stage, tumor differentiation, gender, and age. 27754705 2016
Secondary malignant neoplasm of lymph node
0.090 Biomarker disease BEFREE CDX2 might be valuable in terms of narrowing the possible sites of origin to be considered in the setting of SCC with unknown primary presenting with inguinal lymph node metastasis. 23105122 2013
Secondary malignant neoplasm of lymph node
0.090 Biomarker disease BEFREE The CDX2/CK20 phenotype was associated with older age (above 56 y), higher stage (stage III or IV), deep invasion (pT3 or pT4), lymph node metastasis (pN1 or pN2), poor differentiation (nonmedullary/non-signet ring cell type), the mutation of BRAF, and CIMP-H status among MSI-H CRCs. 24025523 2013
Secondary malignant neoplasm of lymph node
0.090 AlteredExpression disease BEFREE ITLN-1 positivity in gastric cancer was positively correlated with tumor differentiation (P = 0.001) and CDX2 expression (P < 0.001), and inversely correlated with depth of invasion (P = 0.007), lymph node metastasis (P = 0.001), distant metastasis (P = 0.014), clinical stage (P = 0.006), Ki-67 expression (P = 0.001), and heparanase expression (P < 0.001), without correlation with age, gender, tumor location, or tumor size. 22083213 2012
Secondary malignant neoplasm of lymph node
0.090 Biomarker disease BEFREE Cdx2-positive cases were significantly associated with higher male-to-female ratio (RR=1.27, 95% CI: 1.17-1.38, P<0.00001 fixed-effect), lower (I+II) clinical stage (RR=1.63, 95% CI: 1.42-1.87, P<0.00001 fixed-effect), better histologic differentiation (RR=1.54, 95% CI: 1.34-1.76, P<0.00001 fixed-effect), and lower rate of vascular invasion (RR=1.23, 95% CI: 1.08-1.41, P=0.002 fixed-effect) and lymph node metastasis (RR=1.52, 95% CI: 1.33-1.73, P<0.00001 fixed-effect), as well as higher 5-year survival rate (HR=2.22, 95% CI: 1.78-2.75, P<0.00001 fixed-effect). 23181722 2012
Secondary malignant neoplasm of lymph node
0.090 Biomarker disease BEFREE Of the 62 cases of CRC examined, 43 (69.4%) and 39 (62.9%) were positive for CDX2 and HIF-1alpha, respectively, such that their expression was correlated with differentiation grade, tumor stage and lymph node metastasis (chi2 test, p<0.01). 20514449 2010
Secondary malignant neoplasm of lymph node
0.090 AlteredExpression disease BEFREE Recently, an inverse correlation between CDX2 expression and tumor grade, tumor stage and lymph node metastasis in colorectal adenocarcinomas has been reported. 19795349 2009